NZ714128A - 4-1bb binding molecules - Google Patents

4-1bb binding molecules

Info

Publication number
NZ714128A
NZ714128A NZ714128A NZ71412811A NZ714128A NZ 714128 A NZ714128 A NZ 714128A NZ 714128 A NZ714128 A NZ 714128A NZ 71412811 A NZ71412811 A NZ 71412811A NZ 714128 A NZ714128 A NZ 714128A
Authority
NZ
New Zealand
Prior art keywords
binding molecules
disclosed
extracellular domain
cdr sequences
binds human
Prior art date
Application number
NZ714128A
Other languages
English (en)
Inventor
Bianca Ahrens
Sangita M Baxi
Simon Paul Bergqvist
Regis Doyonnas
Robert Lee Dufield
Mark William Elliott
Timothy Scott Fisher
Richard Michael Jerome
Heather Laurence Jones
Cris Kamperschroer
Kathrin Ladetzki-Baehs
Victoria Alexandria Love
Theodore Lawrence Oliphant
Adekunle Olatunbosun Onadipe
Wenning Qin
Vinay Radhakrishnan
Allison Karlyn Rohner
Leslie Lynne Sharp
Michael Tesar
Kristin Elizabeth Thomas
Libbey Anne Yates
Daisy Marie Ziegemeier
Moritz Zulley
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Priority to NZ729044A priority Critical patent/NZ729044A/en
Publication of NZ714128A publication Critical patent/NZ714128A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ714128A 2010-09-09 2011-08-26 4-1bb binding molecules NZ714128A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ729044A NZ729044A (en) 2010-09-09 2011-08-26 4-1bb binding molecules

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38121010P 2010-09-09 2010-09-09
NZ700891A NZ700891A (en) 2010-09-09 2011-08-26 4-1bb binding molecules

Publications (1)

Publication Number Publication Date
NZ714128A true NZ714128A (en) 2017-10-27

Family

ID=44759732

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ714128A NZ714128A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ607710A NZ607710A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ700891A NZ700891A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ729044A NZ729044A (en) 2010-09-09 2011-08-26 4-1bb binding molecules

Family Applications After (3)

Application Number Title Priority Date Filing Date
NZ607710A NZ607710A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ700891A NZ700891A (en) 2010-09-09 2011-08-26 4-1bb binding molecules
NZ729044A NZ729044A (en) 2010-09-09 2011-08-26 4-1bb binding molecules

Country Status (27)

Country Link
US (5) US8337850B2 (enExample)
EP (2) EP3441404A1 (enExample)
JP (4) JP6105470B2 (enExample)
KR (2) KR101527297B1 (enExample)
CN (2) CN105481983B (enExample)
AR (2) AR082916A1 (enExample)
AU (3) AU2011300445B2 (enExample)
BR (1) BR112013005699B1 (enExample)
CA (1) CA2810359C (enExample)
CO (1) CO6690759A2 (enExample)
DK (1) DK2614082T3 (enExample)
ES (1) ES2699648T3 (enExample)
HU (1) HUE041958T2 (enExample)
IL (3) IL225001A (enExample)
MX (2) MX374682B (enExample)
MY (2) MY162737A (enExample)
NZ (4) NZ714128A (enExample)
PE (1) PE20131465A1 (enExample)
PH (2) PH12013500395B1 (enExample)
PL (1) PL2614082T3 (enExample)
PT (1) PT2614082T (enExample)
RU (2) RU2710717C2 (enExample)
SG (3) SG10201506906VA (enExample)
SI (1) SI2614082T1 (enExample)
TW (4) TWI520969B (enExample)
WO (1) WO2012032433A1 (enExample)
ZA (1) ZA201502914B (enExample)

Families Citing this family (412)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2614082T1 (sl) * 2010-09-09 2018-12-31 Pfizer Inc. Molekule, ki vežejo 4-1BB
WO2012088446A1 (en) 2010-12-22 2012-06-28 Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
DK2699598T3 (en) * 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
SG10202006507XA (en) 2012-05-30 2020-08-28 Chugai Pharmaceutical Co Ltd Target-tissue-specific antigen-binding molecule
US9834610B2 (en) * 2013-01-31 2017-12-05 Thomas Jefferson University Fusion proteins for modulating regulatory and effector T cells
ES2935257T3 (es) 2013-03-15 2023-03-03 Univ Chicago Métodos y composiciones relacionadas con la actividad de las células T
WO2014163101A1 (ja) 2013-04-02 2014-10-09 中外製薬株式会社 Ｆｃ領域改変体
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
US20160264670A1 (en) * 2013-11-06 2016-09-15 Bristol-Myers Squibb Company Immunotherapeutic dosing regimens and combinations thereof
EP3078744B1 (en) 2013-12-04 2020-08-26 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecules, the antigen-binding activity of which varies according to the concentration of compounds, and libraries of said molecules
PL3466949T3 (pl) 2013-12-24 2021-05-31 Bristol-Myers Squibb Company Związek tricykliczny jako środki przeciwrakowe
ES2783026T3 (es) 2014-02-04 2020-09-16 Pfizer Combinación de un antagonista de PD-1 y un agonista de 4-1BB para el tratamiento de cáncer
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
EP3134102B1 (en) 2014-04-24 2019-07-03 The Board of Trustees of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
EP3145956A1 (en) 2014-05-21 2017-03-29 Pfizer Inc. Combination of an anti-ccr4 antibody and a 4-1bb agonist for treating cancer
SMT201900668T1 (it) 2014-06-06 2020-01-14 Bristol Myers Squibb Co Anticorpi contro il recettore per il fattore di necrosi tumorale indotto da glucocorticoidi(gitr)e loro usi
CA2951259A1 (en) 2014-06-06 2015-12-10 Flexus Biosciences, Inc. Immunoregulatory agents
US10695426B2 (en) 2014-08-25 2020-06-30 Pfizer Inc. Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer
ES2870449T3 (es) 2014-10-29 2021-10-27 Bicyclerd Ltd Ligandos peptídicos bicíclicos específicos de MT1-MMP
AR102537A1 (es) 2014-11-05 2017-03-08 Flexus Biosciences Inc Agentes inmunomoduladores
MX2017005462A (es) 2014-11-05 2017-07-28 Flexus Biosciences Inc Agentes inmunorreguladores.
UY36390A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
EA035766B1 (ru) 2014-11-21 2020-08-07 Бристол-Майерс Сквибб Компани Антитело к cd73 и его применения
AR103232A1 (es) 2014-12-22 2017-04-26 Bristol Myers Squibb Co ANTAGONISTAS DE TGFbR
PL3247728T3 (pl) 2015-01-20 2020-11-16 Igm Biosciences, Inc. Cząsteczki wiążące receptor nadrodziny czynnika martwicy nowotworów (TNF) i ich stosowanie
WO2016127052A1 (en) 2015-02-05 2016-08-11 Bristol-Myers Squibb Company Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy
MX2017010793A (es) 2015-02-22 2018-07-06 Sorrento Therapeutics Inc Terapeuticos de anticuerpo que ligan cd137.
EP4279087A3 (en) 2015-02-26 2024-01-31 Merck Patent GmbH Pd-1 / pd-l1 inhibitors for the treatment of cancer
SG11201705821XA (en) 2015-03-02 2017-08-30 Rigel Pharmaceuticals Inc TGF-ß INHIBITORS
EP3973980A1 (en) * 2015-03-31 2022-03-30 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
US10399933B2 (en) 2015-04-03 2019-09-03 Bristol-Myers Squibb Company Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer
WO2016162505A1 (en) 2015-04-08 2016-10-13 F-Star Biotechnology Limited Her2 binding agent therapies
JP6971850B2 (ja) 2015-04-13 2021-11-24 ファイヴ プライム セラピューティクス インク がんの併用療法
ES2815683T3 (es) 2015-05-11 2021-03-30 Bristol Myers Squibb Co Compuestos tricíclicos como agentes antineoplásicos
EP3307740B1 (en) 2015-05-12 2019-12-18 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
MX390894B (es) * 2015-05-18 2025-03-21 Pieris Pharmaceuticals Gmbh Polipéptido de fusión anti-cáncer.
EP3298045A1 (en) 2015-05-21 2018-03-28 Alligator Bioscience AB Novel polypeptides
GB201509338D0 (en) 2015-05-29 2015-07-15 Bergenbio As Combination therapy
PT3303396T (pt) 2015-05-29 2023-01-30 Bristol Myers Squibb Co Anticorpos contra ox40 e utilizações dos mesmos
PH12017501857B1 (en) 2015-06-16 2024-01-17 Merck Patent Gmbh Pd-l1 antagonist combination treatments
EP3744340A3 (en) 2015-07-16 2021-03-03 Biokine Therapeutics Ltd. Compositions and methods for treating cancer
US10399987B2 (en) 2015-07-28 2019-09-03 Bristol-Myer Squibb Company TGF beta receptor antagonists
US20180230431A1 (en) 2015-08-07 2018-08-16 Glaxosmithkline Intellectual Property Development Limited Combination Therapy
US20180250303A1 (en) 2015-08-25 2018-09-06 Bristol-Myers Squibb Company Tgf beta receptor antagonists
EP3354661B1 (en) * 2015-09-22 2020-06-03 Dingfu Biotarget Co., Ltd. Fully human antibody against human cd137 and use thereof
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
EP4046655A1 (en) 2015-11-03 2022-08-24 Janssen Biotech, Inc. Antibodies specifically binding pd-1 and their uses
GB201519481D0 (en) * 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
KR20180082563A (ko) 2015-11-19 2018-07-18 브리스톨-마이어스 스큅 컴퍼니 글루코코르티코이드-유도된 종양 괴사 인자 수용체 (gitr)에 대한 항체 및 그의 용도
KR20250034528A (ko) 2015-11-23 2025-03-11 파이브 프라임 테라퓨틱스, 인크. 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
JP6856648B2 (ja) 2015-12-15 2021-04-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｘｃｒ４受容体アンタゴニスト
BR112018013677A2 (pt) 2016-01-11 2019-01-22 Inhibrx, Inc. proteínas de fusão de ligação de 41bb multivalentes e multiespecíficas
CA2955184A1 (en) * 2016-01-25 2017-07-25 Pfizer Inc. Combination of an ox40 agonist and a 4-1bb agonist for treating cancer
CN109476740A (zh) 2016-03-04 2019-03-15 百时美施贵宝公司 利用抗cd73抗体的联合治疗
EP3445783A2 (en) 2016-04-18 2019-02-27 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
JP2019516681A (ja) 2016-05-04 2019-06-20 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
JP2019519485A (ja) 2016-05-04 2019-07-11 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法
EP3452030A4 (en) 2016-05-04 2019-11-13 Bristol-Myers Squibb Company INHIBITORS OF INDOLEAMINE-2,3-DIOXYGENASE AND METHOD FOR THEIR USE
CN109348714A (zh) 2016-05-04 2019-02-15 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
US11066383B2 (en) 2016-05-04 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN109476747A (zh) 2016-05-27 2019-03-15 艾伯维生物制药股份有限公司 结合免疫调节性蛋白和肿瘤抗原的双特异性结合蛋白
WO2017205745A1 (en) * 2016-05-27 2017-11-30 Abbvie Biotherapeutics Inc. Anti-4-1bb antibodies and their uses
AU2017204125B1 (en) 2016-06-17 2017-10-26 Crispr Therapeutics Ag Compositions and methods for the depletion of cd117+ cells
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
CN109311993B (zh) 2016-06-20 2022-12-20 F-星治疗有限公司 Lag-3结合元件
EA201990293A1 (ru) 2016-07-14 2019-07-31 Генмаб А/С Мультиспецифичные антитела против cd40 и cd137
PE20190418A1 (es) 2016-07-14 2019-03-19 Bristol Myers Squibb Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
GB201612520D0 (en) 2016-07-19 2016-08-31 F-Star Beta Ltd Binding molecules
WO2018017633A1 (en) 2016-07-21 2018-01-25 Bristol-Myers Squibb Company TGF Beta RECEPTOR ANTAGONISTS
MA45919A (fr) 2016-08-12 2019-06-19 Janssen Biotech Inc Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
WO2018031400A1 (en) 2016-08-12 2018-02-15 Janssen Biotech, Inc. Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them
US11246905B2 (en) 2016-08-15 2022-02-15 President And Fellows Of Harvard College Treating infections using IdsD from Proteus mirabilis
KR20230145510A (ko) 2016-08-17 2023-10-17 컴퓨젠 엘티디. 항-tigit 항체, 항-pvrig 항체 및 이들의 조합
CN106244611B (zh) * 2016-08-23 2019-05-17 浙江普康生物技术股份有限公司 一种细胞免疫佐剂tsa-41的制备方法及应用
CN109843322A (zh) 2016-08-26 2019-06-04 百时美施贵宝公司 吲哚胺2,3-双加氧酶的抑制剂及其使用方法
AU2017332452B2 (en) 2016-09-23 2021-01-07 Merus N.V. Binding molecules that modulate a biological activity expressed by a cell
CA3039451A1 (en) 2016-10-06 2018-04-12 Pfizer Inc. Dosing regimen of avelumab for the treatment of cancer
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10899842B2 (en) 2016-11-23 2021-01-26 Immunoah Therapeutics, Inc. 4-1BB binding proteins and uses thereof
US10961239B2 (en) 2017-01-05 2021-03-30 Bristol-Myers Squibb Company TGF beta receptor antagonists
JP7780248B2 (ja) 2017-01-06 2025-12-04 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍壊死因子受容体スーパーファミリー（ｔｎｆｒｓｆ）アゴニストによる腫瘍浸潤リンパ球（ｔｉｌ）の拡大培養及びｔｉｌとｔｎｆｒｓｆアゴニストとの治療的併用
US10174122B2 (en) * 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
CN110740748A (zh) 2017-01-17 2020-01-31 芝加哥大学 肿瘤微环境中功能障碍的抗原特异性cd8+t细胞
MA47331A (fr) 2017-01-20 2019-11-27 Magenta Therapeutics Inc Compositions et procédés pour la déplétion des cellules cd137+
NZ754731A (en) 2017-01-20 2023-02-24 Arcus Biosciences Inc Azolopyrimidine for the treatment of cancer-related disorders
MA47449A (fr) 2017-02-10 2019-12-18 Genmab Bv Variants polypeptidiques et ses utilisations
MA47612A (fr) 2017-02-24 2020-01-01 Macrogenics Inc Molécules de liaison bispécifiques capables de se lier à cd137 et à des antigènes tumoraux, et leurs utilisations
JP2020512357A (ja) 2017-03-31 2020-04-23 ファイブ プライム セラピューティクス， インコーポレイテッド 抗ｇｉｔｒ抗体を使用した癌の併用療法
KR20240017409A (ko) 2017-04-13 2024-02-07 아게누스 인코포레이티드 항-cd137 항체 및 이의 사용 방법
CN110831600B (zh) 2017-04-21 2023-10-17 医肯纳肿瘤学公司 吲哚ahr抑制剂和其用途
WO2018201014A1 (en) 2017-04-28 2018-11-01 Five Prime Therapeutics, Inc. Methods of treatment with cd80 extracellular domain polypeptides
US11066392B2 (en) 2017-05-12 2021-07-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
EP3634417B1 (en) 2017-05-17 2023-07-12 Arcus Biosciences, Inc. Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
CA3064331A1 (en) 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
AR112072A1 (es) 2017-06-05 2019-09-18 Iovance Biotherapeutics Inc Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
CA3061959A1 (en) 2017-06-09 2018-12-13 Providence Health & Services - Oregon Utilization of cd39 and cd103 for identification of human tumor reactive t cells for treatment of cancer
US11542312B2 (en) 2017-06-19 2023-01-03 Medicenna Therapeutics, Inc. IL-2 superagonists in combination with anti-PD-1 antibodies
CN110869389B (zh) * 2017-06-25 2023-07-28 西雅图免疫公司 抗ror1抗体及其制备和使用方法
CA3066789A1 (en) 2017-06-30 2019-01-03 Bristol-Myers Squibb Company Amorphous and crystalline forms of ido inhibitors
CN111278858B (zh) 2017-07-11 2024-07-23 指南针制药有限责任公司 结合人cd137的激动剂抗体及其用途
CA3070272A1 (en) 2017-07-20 2019-01-24 Aptevo Research And Development Llc Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
ES2932354T3 (es) 2017-07-28 2023-01-18 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticáncer
PE20200839A1 (es) * 2017-08-01 2020-08-13 Lilly Co Eli Anticuerpos anti-cd137
US11512134B2 (en) 2017-08-01 2022-11-29 Eli Lilly And Company Anti-CD137 antibodies
WO2019025811A1 (en) 2017-08-04 2019-02-07 Bicycletx Limited SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137
BR112020003116A2 (pt) 2017-08-17 2020-08-04 Ikena Oncology, Inc. inibidores de ahr e usos dos mesmos
WO2019036855A1 (en) 2017-08-21 2019-02-28 Adagene Inc. Anti-cd137 molecules and use thereof
JP7316263B2 (ja) 2017-08-31 2023-07-27 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
JP7208225B2 (ja) 2017-08-31 2023-01-18 ブリストル－マイヤーズ スクイブ カンパニー 抗癌剤としての環状ジヌクレオチド
EP3676278B1 (en) 2017-08-31 2023-04-12 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
JP7366031B2 (ja) 2017-09-22 2023-10-20 カイメラ セラピューティクス， インコーポレイテッド タンパク質分解剤およびそれらの使用
EP3684366A4 (en) 2017-09-22 2021-09-08 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
US11649212B2 (en) 2017-10-09 2023-05-16 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
WO2019074824A1 (en) 2017-10-09 2019-04-18 Bristol-Myers Squibb Company INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
AU2018348431B2 (en) * 2017-10-10 2025-10-02 Numab Therapeutics AG Antibodies targeting CD137 and methods of use thereof
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
EP3470428A1 (en) 2017-10-10 2019-04-17 Numab Innovation AG Antibodies targeting cd137 and methods of use thereof
WO2019074887A1 (en) 2017-10-10 2019-04-18 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
CA3075969A1 (en) 2017-10-10 2019-04-18 Numab Therapeutics AG Multispecific antibody
EP3470426A1 (en) 2017-10-10 2019-04-17 Numab Therapeutics AG Multispecific antibody
CN109651507B (zh) * 2017-10-12 2021-11-26 瑞阳(苏州)生物科技有限公司 一种激动型4-1bb单克隆抗体
WO2019079261A1 (en) 2017-10-16 2019-04-25 Bristol-Myers Squibb Company CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
CN111542544A (zh) 2017-11-01 2020-08-14 百时美施贵宝公司 用于治疗癌症的免疫刺激性激动性抗体
WO2019090198A1 (en) 2017-11-06 2019-05-09 Bristol-Myers Squibb Company Isofuranone compounds useful as hpk1 inhibitors
EP3706803A4 (en) 2017-11-08 2021-08-04 Yafei Shanghai Biolog Medicine Science & Technology Co., Ltd. CONJUGATES BASED ON A BIOMOLECULE AND THEIR USE
TWI701259B (zh) * 2017-11-09 2020-08-11 大陸商上海懷越生物科技有限公司 ４﹘１ｂｂ抗體及其製備方法和應用
MX2020004967A (es) 2017-11-17 2020-08-27 Iovance Biotherapeutics Inc Expansion de linfocitos infiltrantes del tumor (til) de aspirados con aguja fina y biopsias por puncion.
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019109238A1 (en) 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
CN110003332B (zh) * 2018-01-05 2021-05-11 上海原能细胞医学技术有限公司 Cd137抗体及其应用
US11447449B2 (en) 2018-01-05 2022-09-20 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP2021509586A (ja) 2018-01-08 2021-04-01 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍抗原特異的ｔ細胞について濃縮されたｔｉｌ製品を生成するためのプロセス
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
EP3737675A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
KR102813913B1 (ko) 2018-01-12 2025-05-30 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
EP3737666A4 (en) 2018-01-12 2022-01-05 Kymera Therapeutics, Inc. PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
CN111867680A (zh) 2018-01-15 2020-10-30 辉瑞大药厂 组合施用嵌合抗原受体免疫疗法与4-1bb激动剂的方法
US20210363266A1 (en) * 2018-01-22 2021-11-25 Jiangsu Hengrui Medicine Co., Ltd. Anti-4-1bb antibody, antigen-binding fragment thereof and medical use thereof
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
BR112020015396A2 (pt) 2018-01-29 2020-12-08 Merck Patent Gmbh Inididores de gcn2 e usos dos mesmos
IL301089A (en) 2018-01-29 2023-05-01 Vertex Pharma GCN2 inhibitors and their uses
WO2019148445A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Precision/context-dependent activatable antibodies, and methods of making and using the same
US10519187B2 (en) 2018-02-13 2019-12-31 Bristol-Myers Squibb Company Cyclic dinucleotides as anticancer agents
CA3090795A1 (en) 2018-02-13 2019-08-22 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
JP7417527B2 (ja) 2018-02-16 2024-01-18 アーカス バイオサイエンシズ インコーポレイティド アゾロピリミジン化合物による投薬
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
CR20200445A (es) 2018-03-05 2021-04-27 Arcus Biosciences Inc Inhibidores de la arginasa
KR20200130362A (ko) 2018-03-08 2020-11-18 브리스톨-마이어스 스큅 컴퍼니 항암제로서의 시클릭 디뉴클레오티드
WO2019173798A1 (en) 2018-03-08 2019-09-12 Rubius Therapeutics, Inc. Therapeutic cell systems and methods for treating cancer and infectious diseases
JP7510879B2 (ja) 2018-03-21 2024-07-04 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
MX2020009864A (es) 2018-03-23 2021-01-08 Lilly Co Eli Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1.
CA3094763C (en) * 2018-03-23 2024-01-02 Eli Lilly And Company Anti-cd137 antibodies for combination with anti-pd-l1 antibodies
EA202092319A1 (ru) 2018-03-29 2021-03-04 Айовэнс Байотерапьютикс, Инк. Способы получения опухоль-инфильтрирующих лимфоцитов и применения их в иммунотерапии
US11993655B2 (en) 2018-04-09 2024-05-28 Oricell Therapeutics Co., Ltd. Anti-PD-L1 antibody and use thereof
WO2019196868A1 (en) 2018-04-10 2019-10-17 Wuxi Biologics (Shanghai) Co., Ltd. A monoclonal antibody against human 4-1bb, method for preparing the same, and use thereof
BR112020020826A2 (pt) 2018-04-12 2021-01-19 Bristol-Myers Squibb Company Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1
JP7418346B2 (ja) 2018-04-13 2024-01-19 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト ４－１ＢＢＬを含むＨｅｒ２標的化抗原結合分子
JP2021522211A (ja) 2018-04-16 2021-08-30 アリーズ セラピューティクス， インコーポレイテッド Ｅｐ４阻害剤およびその使用
SG11202010319RA (en) 2018-04-27 2020-11-27 Iovance Biotherapeutics Inc Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
US12037323B2 (en) 2018-05-03 2024-07-16 Bristol-Myers Squibb Company Uracil derivatives as Mer-AXL inhibitors
US12473532B2 (en) 2018-05-10 2025-11-18 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2021528393A (ja) 2018-06-15 2021-10-21 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 後細胞シグナル伝達因子の調節による免疫活性の上昇
IL279489B2 (en) 2018-06-22 2025-10-01 Bicycletx Ltd Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate
RS64641B1 (sr) 2018-06-27 2023-10-31 Bristol Myers Squibb Co Supstituisana jedinjenja naftiridinona korisna kao aktivatori t ćelija
FI3814347T3 (fi) 2018-06-27 2023-06-12 Bristol Myers Squibb Co Naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
TWI819024B (zh) 2018-07-09 2023-10-21 美商戊瑞治療有限公司 結合至ｉｌｔ４的抗體
SG11202100102VA (en) 2018-07-11 2021-02-25 Five Prime Therapeutics Inc Antibodies binding to vista at acidic ph
AU2019301206B2 (en) 2018-07-12 2025-10-30 Invox Pharma Limited Antibody molecules that bind CD137 and OX40
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
ES3006183T3 (en) 2018-07-12 2025-03-17 Invox Pharma Ltd Antibody molecules that bind pd-l1 and cd137
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
WO2020018680A1 (en) 2018-07-18 2020-01-23 Arcus Biosciences, Inc. Solid forms of an azolopyrimidine compound
WO2020018354A1 (en) 2018-07-19 2020-01-23 Eli Lilly And Company Bispecific antibodies targeting immune checkpoints
WO2020023356A1 (en) 2018-07-23 2020-01-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US12059420B2 (en) 2018-07-23 2024-08-13 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
WO2020023553A1 (en) 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
KR102809468B1 (ko) 2018-07-27 2025-05-19 아르커스 바이오사이언시즈 인코포레이티드 피리돈 a2r 길항제
KR102697702B1 (ko) 2018-08-10 2024-08-22 추가이 세이야쿠 가부시키가이샤 항cd137 항원 결합 분자 및 그의 사용
US10959986B2 (en) 2018-08-29 2021-03-30 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US11253525B2 (en) 2018-08-29 2022-02-22 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
JP2022500499A (ja) 2018-09-07 2022-01-04 ピク セラピューティクス， インコーポレイテッド Ｅｉｆ４ｅ阻害剤およびその使用
JP7658896B2 (ja) 2018-09-20 2025-04-08 アイオバンス バイオセラピューティクス，インコーポレイテッド 凍結保存腫瘍サンプルからのｔｉｌの拡大培養
EP3636320A1 (en) 2018-10-09 2020-04-15 Numab Therapeutics AG Antibodies targeting cd137 and methods of use thereof
TWI839395B (zh) 2018-10-09 2024-04-21 瑞士商Ｎｕｍａｂ治療公司 靶向cd137的抗體及其使用方法
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
TW202028245A (zh) 2018-10-11 2020-08-01 美商英伊布里克斯公司 Dll3單域抗體及其治療性組合物
CA3115285A1 (en) 2018-10-11 2020-04-16 Inhibrx, Inc. Pd-1 single domain antibodies and therapeutic compositions thereof
CA3118634A1 (en) 2018-11-05 2020-05-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients refractory for anti-pd-1 antibody
JP2022506508A (ja) 2018-11-05 2022-01-17 アイオバンス バイオセラピューティクス，インコーポレイテッド Ａｋｔ経路阻害剤を利用したｔｉｌの拡大培養
KR20210099573A (ko) 2018-11-05 2021-08-12 이오반스 바이오테라퓨틱스, 인크. 개선된 종양 반응성 t-세포의 선택
US12453697B2 (en) 2018-11-05 2025-10-28 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3120196A1 (en) 2018-11-16 2020-05-22 Arcus Biosciences, Inc. Inhibitors of arg1 and/or arg2
MY206649A (en) * 2018-11-30 2024-12-30 I Mab Biopharma Us Ltd Anti-pd-l1/anti-4-1bb bispecific antibodies and uses thereof
PH12021500026A1 (en) 2018-11-30 2022-05-11 Kymera Therapeutics Inc Irak degraders and uses thereof
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
EP3898949A1 (en) 2018-12-19 2021-10-27 Iovance Biotherapeutics, Inc. Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof
EP3670659A1 (en) 2018-12-20 2020-06-24 Abivax Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
WO2020128893A1 (en) 2018-12-21 2020-06-25 Pfizer Inc. Combination treatments of cancer comprising a tlr agonist
JP2022514618A (ja) 2018-12-21 2022-02-14 バイスクルテクス・リミテッド Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド
JP7558534B2 (ja) * 2019-01-02 2024-10-01 キューエルエスエフ バイオセラピューティック インコーポレイテッド Ｃｄ１３７アゴニスト性抗体とその使用
KR20210131312A (ko) * 2019-01-16 2021-11-02 콤파스 테라퓨틱스 엘엘씨 인간 cd137에 결합하는 항체의 제제 및 이의 용도
MX2021010039A (es) 2019-02-26 2021-09-21 Pieris Pharmaceuticals Gmbh Novedosas proteinas de fusion especificas para cd137 y gpc3.
EP3937964A4 (en) 2019-03-12 2022-11-16 Arcus Biosciences, Inc. TREATMENT OF ONCOGENE-DRIVEN CANCERS
EA202192555A1 (ru) 2019-03-19 2021-11-25 Фундасио Привада Институт Д'Инвестигасио Онколохика Де Валь Эброн Комбинированная терапия для лечения рака
CN113874397A (zh) 2019-03-29 2021-12-31 艾库斯生物科学有限公司 利用鉴定的腺苷指纹治疗癌症
KR20220002336A (ko) 2019-03-29 2022-01-06 미스트 쎄라퓨틱스, 엘엘씨 T 세포 치료제를 제조하기 위한 생체외 방법 및 관련 조성물 및 방법
JP2022528887A (ja) 2019-04-02 2022-06-16 バイスクルテクス・リミテッド バイシクルトキシンコンジュゲートおよびその使用
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
CA3137373A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
WO2020231809A1 (en) 2019-05-10 2020-11-19 Lyvgen Biopharma Co., Ltd. Humanized anti-cd137 antibodies and uses thereof
US12012374B2 (en) 2019-05-13 2024-06-18 Bristol-Myers Squibb Company Agonists of ROR GAMMAt
US20220249559A1 (en) 2019-05-13 2022-08-11 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020231766A1 (en) 2019-05-13 2020-11-19 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
CN113874036A (zh) 2019-05-24 2021-12-31 辉瑞公司 使用cdk抑制剂的联合治疗
EP3976043A1 (en) 2019-05-24 2022-04-06 Pfizer Inc. Combination therapies using cdk inhibitors
BR112021024224A2 (pt) 2019-05-31 2022-04-26 Ikena Oncology Inc Inibidores de tead e usos dos mesmos
SG11202112921VA (en) 2019-06-04 2021-12-30 Molecular Partners Ag Multispecific proteins
US12521438B2 (en) 2019-06-10 2026-01-13 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2021026179A1 (en) 2019-08-06 2021-02-11 Bristol-Myers Squibb Company AGONISTS OF ROR GAMMAt
AR119821A1 (es) 2019-08-28 2022-01-12 Bristol Myers Squibb Co Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
PH12022550605A1 (en) 2019-09-13 2023-09-25 Nimbus Saturn Inc Hpk1 antagonists and uses thereof
JP7650867B2 (ja) 2019-09-19 2025-03-25 ブリストル－マイヤーズ スクイブ カンパニー 酸性ｐＨでＶＩＳＴＡと結合する抗体
CN114728946A (zh) 2019-09-25 2022-07-08 辉瑞公司 Sting (干扰素基因刺激剂)的多杂环调节剂
EP4048295A1 (en) 2019-10-25 2022-08-31 Iovance Biotherapeutics, Inc. Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
CN114269788B (zh) 2019-11-13 2024-08-20 合肥瀚科迈博生物技术有限公司 一种能够与人4-1bb结合的分子及其应用
CN112898426A (zh) 2019-11-19 2021-06-04 非同（成都）生物科技有限公司 人源化4-1bb单克隆抗体及其药物组合物
IL293027A (en) 2019-11-19 2022-07-01 Bristol Myers Squibb Co Compounds useful as inhibitors of Helios protein
FI4065582T3 (fi) 2019-11-26 2025-05-25 Ikena Oncology Inc Polymorfisia karbatsolijohdannaisia ja niiden käyttötapoja
BR112022009944A2 (pt) 2019-11-26 2022-08-09 Bristol Myers Squibb Co Sais / cocristais de (r)-n-(4-clorofenil)-2-((1s,4s)-4-(6-fluoroquinolin-4-il)ciclo-hexil)propanamida
EP4065229A1 (en) 2019-11-27 2022-10-05 Myst Therapeutics, LLC Method of producing tumor-reactive t cell composition using modulatory agents
CA3161104A1 (en) 2019-12-11 2021-06-17 Cecile Chartier-Courtaud Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
EP4076520A4 (en) 2019-12-17 2024-03-27 Kymera Therapeutics, Inc. IRAQ DEGRADATION AGENTS AND THEIR USES
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
IL293351A (en) 2019-12-18 2022-07-01 Pfizer Once daily cancer treatment regimen with a prmt5 inhibitor
IL294273A (en) 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted heteroaryl compounds are useful as t-cell activators
AR120823A1 (es) 2019-12-23 2022-03-23 Bristol Myers Squibb Co Compuestos bicíclicos sustituidos útiles como activadores de células t
EP4081516B1 (en) 2019-12-23 2025-07-30 Bristol-Myers Squibb Company Substituted quinazolinyl compounds useful as t cell activators
CN115297931A (zh) 2019-12-23 2022-11-04 凯麦拉医疗公司 Smarca降解剂和其用途
BR112022012220A2 (pt) 2019-12-23 2022-09-13 Bristol Myers Squibb Co Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t
KR20220120624A (ko) 2019-12-23 2022-08-30 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 치환된 피페라진 유도체
CA3166898A1 (en) 2020-01-06 2021-07-15 Hifibio (Hk) Limited Anti-tnfr2 antibody and uses thereof
WO2021139682A1 (en) 2020-01-07 2021-07-15 Hifibio (Hk) Limited Anti-galectin-9 antibody and uses thereof
JP2023509516A (ja) 2020-01-07 2023-03-08 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム がん治療のための改良型ヒトメチルチオアデノシン／アデノシン枯渇酵素変種
CN115279771B (zh) 2020-01-15 2025-03-21 缆图药品公司 Map4k1抑制剂
TWI895351B (zh) * 2020-02-12 2025-09-01 日商中外製藥股份有限公司 用於癌症之治療的抗cd137抗原結合分子
EP4107173A1 (en) 2020-02-17 2022-12-28 Board of Regents, The University of Texas System Methods for expansion of tumor infiltrating lymphocytes and use thereof
BR112022015656A2 (pt) 2020-02-21 2022-09-27 Macrogenics Inc Moléculas de ligação ao cd137, molécula de ligação ao pd-l1, composição farmacêutica, e ácido nucleico
AU2021226903A1 (en) 2020-02-27 2022-10-20 Turnstone Biologics Corp. Methods for ex vivo enrichment and expansion of tumor reactive T cells and related compositions thereof
JP7715722B2 (ja) * 2020-02-28 2025-07-30 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｃｄ１３７コンストラクト及びその使用
AU2021228078A1 (en) 2020-02-28 2022-09-22 Shanghai Henlius Biotech, Inc. Anti-CD137 constructs, multispecific antibody and uses thereof
EP4110827A4 (en) * 2020-02-28 2024-08-14 Shanghai Henlius Biotech, Inc. ANTI-CD137 CONSTRUCTS, MULTISPECIFIC ANTIBODIES AND THEIR USES
CN115515685B (zh) 2020-03-03 2025-04-08 皮克医疗公司 Eif4e抑制剂及其用途
CA3174908A1 (en) 2020-03-09 2021-09-16 Pfizer Inc. Fusion proteins and uses thereof
MX2022011602A (es) 2020-03-19 2023-01-04 Kymera Therapeutics Inc Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos.
AU2021240068A1 (en) 2020-03-19 2022-09-08 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha
TW202140441A (zh) 2020-03-23 2021-11-01 美商必治妥美雅史谷比公司 經取代之側氧基異吲哚啉化合物
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CA3177413A1 (en) 2020-05-04 2021-11-11 Michelle SIMPSON-ABELSON Selection of improved tumor reactive t-cells
MX2022014180A (es) 2020-05-13 2022-12-02 Pfizer Metodos, terapias y usos para tratar cancer.
KR20230012559A (ko) 2020-05-19 2023-01-26 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 결합 분자
KR20230019152A (ko) 2020-06-02 2023-02-07 아르커스 바이오사이언시즈 인코포레이티드 Tigit에 대한 항체
EP4161521A4 (en) 2020-06-03 2024-07-10 Kymera Therapeutics, Inc. DEUTERED IRAQ DEGRADERS AND USES THEREOF
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
WO2021258010A1 (en) 2020-06-19 2021-12-23 Gossamer Bio Services, Inc. Oxime compounds useful as t cell activators
WO2022006179A1 (en) 2020-06-29 2022-01-06 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
PH12023550237A1 (en) 2020-07-30 2024-04-29 Kymera Therapeutics Inc Methods of treating mutant lymphomas
US20230303695A1 (en) 2020-08-10 2023-09-28 Tengfei XIAO Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8
CA3186504A1 (en) 2020-08-17 2022-02-24 Stephen J. Blakemore Bicycle conjugates specific for nectin-4 and uses thereof
US20230340137A1 (en) 2020-09-14 2023-10-26 Pfizer Inc. Methods, therapies and uses for treating cancer
CN114195900B (zh) 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
CN114195894B (zh) * 2020-09-17 2025-02-25 普米斯生物技术(珠海)有限公司 一种靶向4-1bb的抗体及其应用
EP4225330A1 (en) 2020-10-06 2023-08-16 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
US20230416382A1 (en) 2020-10-14 2023-12-28 Five Prime Therapeutics, Inc. Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof
EP3988568A1 (en) 2020-10-21 2022-04-27 Numab Therapeutics AG Combination treatment
CN114457026A (zh) * 2020-10-30 2022-05-10 未来智人再生医学研究院(广州)有限公司 一种表达4-1bb激活型抗体的多能干细胞及其衍生物与应用
KR20230131189A (ko) 2020-12-02 2023-09-12 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
WO2022120353A1 (en) 2020-12-02 2022-06-09 Ikena Oncology, Inc. Tead inhibitors and uses thereof
TW202241468A (zh) 2020-12-11 2022-11-01 美商艾歐凡斯生物治療公司 用腫瘤浸潤性淋巴球療法與ｂｒａｆ抑制劑及／或ｍｅｋ抑制劑組合治療癌症患者
JP2024501207A (ja) 2020-12-16 2024-01-11 ゴッサマー バイオ サービシズ、インコーポレイテッド Ｔ細胞活性化剤として有用な化合物
WO2022130206A1 (en) 2020-12-16 2022-06-23 Pfizer Inc. TGFβr1 INHIBITOR COMBINATION THERAPIES
AU2021401302A1 (en) 2020-12-17 2023-07-06 Iovance Biotherapeutics, Inc. Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
EP4262827A1 (en) 2020-12-17 2023-10-25 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocytes
KR20230143632A (ko) 2020-12-30 2023-10-12 카이메라 쎄라퓨틱스 인코포레이티드 Irak 분해제 및 이의 용도
US20250186539A2 (en) 2021-01-11 2025-06-12 Bicycletx Limited Methods for treating cancer
WO2022153161A1 (en) 2021-01-14 2022-07-21 Pfizer Inc. Treatment of cancer using a prmt5 inhibitor
MX2023009059A (es) 2021-02-02 2023-09-15 Liminal Biosciences Ltd Antagonistas de gpr84 y usos de estos.
AU2022216810A1 (en) 2021-02-02 2023-08-24 Liminal Biosciences Limited Gpr84 antagonists and uses thereof
US20240109899A1 (en) 2021-02-04 2024-04-04 Bristol-Myers Squibb Company Benzofuran compounds as sting agonists
EP4288140A1 (en) 2021-02-05 2023-12-13 Iovance Biotherapeutics, Inc. Adjuvant therapy for cancer
KR20230146052A (ko) 2021-02-12 2023-10-18 에프. 호프만-라 로슈 아게 암 치료용 비시클릭 테트라히드로아제핀 유도체
EP4291235A4 (en) 2021-02-12 2025-01-08 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
US11773103B2 (en) 2021-02-15 2023-10-03 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
IL304907A (en) 2021-02-15 2023-10-01 Kymera Therapeutics Inc Irak4 degraders and uses thereof
JP2024509184A (ja) 2021-03-05 2024-02-29 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍保存及び細胞培養組成物
US11926625B2 (en) 2021-03-05 2024-03-12 Nimbus Saturn, Inc. HPK1 antagonists and uses thereof
JP2024510176A (ja) 2021-03-08 2024-03-06 ブループリント メディシンズ コーポレイション Ｍａｐ４ｋ１阻害剤
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
US11964978B2 (en) 2021-03-18 2024-04-23 Pfizer Inc. Modulators of STING (stimulator of interferon genes)
EP4313989A4 (en) 2021-03-29 2025-03-05 Nimbus Saturn, Inc. HPK1 ANTAGONISTS AND USES THEREOF
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
AU2022253450A1 (en) 2021-04-05 2023-11-16 Bristol-Myers Squibb Company Pyridinyl substituted oxoisoindoline compounds for the treatment of cancer
PL4320112T3 (pl) 2021-04-06 2025-07-21 Bristol-Myers Squibb Company Związki oksoizoindoliny podstawione pirydynylem
BR112023020781A2 (pt) 2021-04-09 2023-12-19 Nimbus Clio Inc Moduladores de cbl-b e usos dos mesmos
AU2022258968A1 (en) 2021-04-16 2023-10-19 Ikena Oncology, Inc. Mek inhibitors and uses thereof
EP4326287A2 (en) 2021-04-19 2024-02-28 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
TW202309030A (zh) 2021-05-07 2023-03-01 美商凱麥拉醫療公司 Cdk2降解劑及其用途
US20240269180A1 (en) 2021-05-17 2024-08-15 Iovance Biotherapeutics, Inc. Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy
JP2024521706A (ja) 2021-05-21 2024-06-04 アーカス バイオサイエンシーズ，インコーポレーテッド Ａｘｌ化合物
TW202313603A (zh) 2021-05-21 2023-04-01 美商阿克思生物科學有限公司 Axl抑制劑化合物
WO2022261018A1 (en) 2021-06-07 2022-12-15 Providence Health & Services - Oregon Cxcr5, pd-1, and icos expressing tumor reactive cd4 t cells and their use
CA3224374A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
AU2022312496A1 (en) 2021-07-14 2024-02-22 Blueprint Medicines Corporation Heterocyclic compounds as map4k1 inhibitors
TW202321238A (zh) 2021-07-15 2023-06-01 美商纜圖藥品公司 Ｍａｐ４ｋ１抑制劑
JP2024527961A (ja) 2021-07-28 2024-07-26 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｋｒａｓ阻害剤と併用した腫瘍浸潤リンパ球療法によるがん患者の治療
WO2023028238A1 (en) 2021-08-25 2023-03-02 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
JP2024534127A (ja) 2021-08-25 2024-09-18 ピク セラピューティクス， インコーポレイテッド ｅＩＦ４Ｅ阻害剤及びその使用
WO2023049862A1 (en) 2021-09-24 2023-03-30 Iovance Biotherapeutics, Inc. Expansion processes and agents for tumor infiltrating lymphocytes
US20240417482A1 (en) * 2021-10-12 2024-12-19 Concept To Medicine Biotech Co., Ltd. Single-domain 4-1bb antibodies
WO2023064958A1 (en) 2021-10-15 2023-04-20 Compugen Ltd. Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodies
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
EP4422635A4 (en) 2021-10-29 2025-11-26 Kymera Therapeutics Inc IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS
JP2024541969A (ja) 2021-10-29 2024-11-13 アーカス バイオサイエンシズ インコーポレイティド Ｈｉｆ－２アルファの阻害剤及びその使用方法
CA3237410A1 (en) 2021-11-10 2023-05-19 Friedrich Graf Finck VON FINCKENSTEIN Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
WO2023114984A1 (en) 2021-12-17 2023-06-22 Ikena Oncology, Inc. Tead inhibitors and uses thereof
WO2023122778A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Pyridazinone derivatives useful as t cell activators
WO2023122777A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
WO2023122772A1 (en) 2021-12-22 2023-06-29 Gossamer Bio Services, Inc. Oxime derivatives useful as t cell activators
JP2025503987A (ja) 2022-01-28 2025-02-06 アイオバンス バイオセラピューティクス，インコーポレイテッド ペイロードを発現するように操作された腫瘍浸潤リンパ球
EP4472967A2 (en) 2022-01-31 2024-12-11 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CN118946556A (zh) 2022-02-01 2024-11-12 阿维纳斯运营公司 Dgk靶向化合物及其用途
WO2023173057A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2023173053A1 (en) 2022-03-10 2023-09-14 Ikena Oncology, Inc. Mek inhibitors and uses thereof
EP4507704A1 (en) 2022-04-15 2025-02-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023211889A1 (en) 2022-04-25 2023-11-02 Ikena Oncology, Inc. Polymorphic compounds and uses thereof
WO2023215719A1 (en) 2022-05-02 2023-11-09 Arcus Biosciences, Inc. Anti-tigit antibodies and uses of the same
EP4532470A1 (en) 2022-05-25 2025-04-09 Ikena Oncology, Inc. Mek inhibitors and uses thereof
WO2024015251A1 (en) 2022-07-15 2024-01-18 Arcus Biosciences, Inc. Inhibitors of hpk1 and methods of use thereof
US20260028336A1 (en) 2022-07-20 2026-01-29 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
EP4565683A1 (en) 2022-08-01 2025-06-11 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
TW202416972A (zh) 2022-08-02 2024-05-01 英商利米那生物科技有限公司 經取代之吡啶酮gpr84拮抗劑及其用途
EP4565568A1 (en) 2022-08-02 2025-06-11 Liminal Biosciences Limited Heteroaryl carboxamide and related gpr84 antagonists and uses thereof
TW202415650A (zh) 2022-08-02 2024-04-16 英商利米那生物科技有限公司 芳基-三唑基及相關gpr84拮抗劑及其用途
EP4568950A1 (en) 2022-08-08 2025-06-18 Bristol-Myers Squibb Company Substituted tetrazolyl compounds useful as t cell activators
KR20250046310A (ko) 2022-08-09 2025-04-02 브리스톨-마이어스 스큅 컴퍼니 T 세포 활성화제로서 유용한 3급 아민 치환된 비시클릭 화합물
TW202417001A (zh) 2022-08-11 2024-05-01 瑞士商赫孚孟拉羅股份公司 雙環四氫吖呯衍生物
JP2025526683A (ja) 2022-08-11 2025-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二環式テトラヒドロチアゼピン誘導体
IL316935A (en) 2022-08-11 2025-01-01 Hoffmann La Roche TETRAHYDROTHIAZEPINE DERIVATIVES CYCLES
PE20251399A1 (es) 2022-08-11 2025-05-22 Hoffmann La Roche Derivados de tetrahidrotiazepina biciclicos
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024081385A1 (en) 2022-10-14 2024-04-18 Arcus Biosciences, Inc. Hpk1 inhibitors and methods of use thereof
TW202428286A (zh) 2022-10-20 2024-07-16 美商阿克思生物科學有限公司 Ｃｄ７３化合物之凍乾配方
US20240208961A1 (en) 2022-11-22 2024-06-27 PIC Therapeutics, Inc. Eif4e inhibitors and uses thereof
WO2024137865A1 (en) 2022-12-22 2024-06-27 Gossamer Bio Services, Inc. Compounds useful as t cell activators
CN120418287A (zh) 2022-12-30 2025-08-01 艾克隆株式会社 与cd137特异性结合的亲和体及其用途
WO2024151687A1 (en) 2023-01-09 2024-07-18 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
US20240425497A1 (en) 2023-05-05 2024-12-26 Arcus Biosciences, Inc. Cbl-b Inhibitors and Methods of Use Thereof
KR20250019700A (ko) 2023-05-08 2025-02-10 브리스톨-마이어스 스큅 컴퍼니 치환된 페닐 옥사졸론 화합물
AU2024269298A1 (en) 2023-05-10 2025-11-27 Blueprint Medicines Corporation Gsk3a inhibitors and methods of use thereof
US20250011318A1 (en) 2023-05-25 2025-01-09 Arcus Biosciences, Inc. Cbl-b inhibitors and methods of use thereof
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024249540A1 (en) 2023-05-31 2024-12-05 Bristol-Myers Squibb Company Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins
WO2024254227A1 (en) 2023-06-07 2024-12-12 Bristol-Myers Squibb Company Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
WO2024263853A1 (en) 2023-06-23 2024-12-26 Bristol-Myers Squibb Company Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
EP4620470A3 (en) 2023-06-23 2025-10-08 Kymera Therapeutics, Inc. Irak degraders and uses thereof
US20250043017A1 (en) 2023-07-10 2025-02-06 Regeneron Pharmaceuticals, Inc. BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF
WO2025030002A2 (en) 2023-08-02 2025-02-06 Arvinas Operations, Inc. Dgk targeting compounds and uses thereof
TW202523350A (zh) 2023-08-10 2025-06-16 美商輝瑞股份有限公司 治療癌症之方法，療法及用途
WO2025064197A1 (en) 2023-09-02 2025-03-27 Bristol-Myers Squibb Company Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
JP7789280B1 (ja) 2023-09-02 2025-12-19 ブリストル－マイヤーズ スクイブ カンパニー 置換フェニルオキソオキサゾリルピペリジンジオン化合物
WO2025054339A1 (en) 2023-09-08 2025-03-13 Arcus Biosciences, Inc. Triazolopyridine compounds as inhibitors of kit
AR133800A1 (es) 2023-09-13 2025-11-05 Bristol Myers Squibb Co Compuestos de oxoisoindolinil piperidina-2,6-diona sustituida
WO2025072330A1 (en) 2023-09-26 2025-04-03 Arcus Biosciences, Inc. Kit inhibitor compounds and methods of use thereof
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
TW202517260A (zh) 2023-10-06 2025-05-01 美商阿克思生物科學有限公司 Ｃｂｌ—ｂ抑制劑及其使用方法
US20250145590A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096489A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096488A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096494A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096487A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
WO2025096505A1 (en) 2023-10-31 2025-05-08 Bristol-Myers Squibb Company Ubiquitin specific processing protease 1 (usp1) compounds
US12384773B2 (en) 2023-11-02 2025-08-12 Arcus Biosciences, Inc. Thiazole compounds and methods of use thereof
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
US20250230173A1 (en) 2023-12-20 2025-07-17 Arcus Biosciences, Inc. Salt forms of an axl inhibitor
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025226767A1 (en) 2024-04-24 2025-10-30 Bristol-Myers Squibb Company Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
DE68913658T3 (de) 1988-11-11 2005-07-21 Stratagene, La Jolla Klonierung von Immunglobulin Sequenzen aus den variablen Domänen
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
JP3949712B2 (ja) 1991-12-02 2007-07-25 メディカル リサーチ カウンシル 抗体セグメントレパートリー由来でファージに表示される抗自己抗体の産生
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
GB9207479D0 (en) 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
WO1996029348A1 (en) 1995-03-23 1996-09-26 Indiana University Foundation Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases
US5994619A (en) 1996-04-01 1999-11-30 University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus Production of chimeric bovine or porcine animals using cultured inner cell mass cells
EP0948353A1 (en) 1996-10-11 1999-10-13 Bristol-Myers Squibb Company Methods and compositions for immunomodulation
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
EP0953639A1 (en) 1998-04-30 1999-11-03 Boehringer Ingelheim International GmbH FAPalpha-specific antibody with improved producibility
US7504490B1 (en) * 1998-10-16 2009-03-17 Oscient Pharmaceuticals Corporation Nucleic acid and amino acid sequences relating to Apergillus fumigatus for diagnostics and therapeutics
US20030118588A1 (en) 1999-05-22 2003-06-26 Linda Diehl Induction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
EP1990409A3 (en) 1999-07-20 2011-05-18 MorphoSys AG Bacteriophage
ES2344592T3 (es) 2001-01-05 2010-09-01 Pfizer Inc. Anticuerpos frente al receptor del factor de crecimiento similar a la insulina i.
AU2002219221B2 (en) 2001-01-09 2007-05-17 Merck Patent Gmbh Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
ATE477280T1 (de) 2001-06-28 2010-08-15 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
JP4383534B2 (ja) 2001-08-17 2009-12-16 コーリー ファーマシューティカル ゲーエムベーハー 改善した活性を有する組み合わせモチーフ免疫刺激オリゴヌクレオチド
ATE435655T1 (de) * 2001-10-09 2009-07-15 Mayo Foundation Verwendung von agonistischen 4-1bb antikörpern zur erhöhung der immunantwort
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
EP2366718A3 (en) 2002-06-28 2012-05-02 Domantis Limited Ligand
PL375144A1 (en) * 2002-07-30 2005-11-28 Bristol-Myers Squibb Company Humanized antibodies against human 4-1bb
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
JP2006507841A (ja) 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
EP1575672A2 (en) 2002-12-16 2005-09-21 Herbert Schwarz Use of cd137 antagonists for the treatment of tumors
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US20090005257A1 (en) 2003-05-14 2009-01-01 Jespers Laurent S Process for Recovering Polypeptides that Unfold Reversibly from a Polypeptide Repertoire
PL1639011T3 (pl) 2003-06-30 2009-05-29 Domantis Ltd Pegilowane przeciwciała jednodomenowe (dAb)
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
AR046094A1 (es) * 2003-10-10 2005-11-23 Bristol Myers Squibb Co Anticuerpos completamente humanos contra 4-1bb humano
US20060153808A1 (en) 2004-11-17 2006-07-13 Board Of Regents, The Universtiy Of Texas System Cancer immunotherapy incorporating p53
CA2595682A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7189097B2 (en) 2005-02-11 2007-03-13 Winchester Electronics Corporation Snap lock connector
WO2006088447A1 (en) 2005-02-15 2006-08-24 Gtc Biotherapeutics, Inc. An anti-cd137 antibody as an agent in the treatement of cancer and glycosylation variants thereof
KR100694508B1 (ko) * 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
CA2610661A1 (en) 2005-06-03 2006-12-07 Pfizer Products Inc. Combinations of erbb2 inhibitors with other therapeutic agents in the treatment of cancer
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
CA2628747C (en) 2005-11-22 2014-01-21 Incyte Corporation Combinations of hormone therapy agents and metalloprotease inhibitors for the treatment of cancer
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
KR100745488B1 (ko) 2006-07-04 2007-08-02 학교법인 울산공업학원 항-4-1ｂｂ 항체 및 화학 항암제를 포함하는 암 질환 예방및 치료용 약학 조성물
US20100150937A1 (en) 2006-11-07 2010-06-17 Sparrow Carl P Antagonists of pcsk9
EP2591787A1 (en) 2007-08-13 2013-05-15 Pfizer Inc Combination motif immune stimulatory oligonucleotides with improved activity
AU2008338591B8 (en) 2007-12-14 2014-02-20 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
EP2281002A2 (en) 2008-04-25 2011-02-09 MorphoSys AG Anti-alk1 antibodies and uses thereof
US8745699B2 (en) * 2010-05-14 2014-06-03 Authentify Inc. Flexible quasi out of band authentication architecture
MX346912B (es) 2009-12-07 2017-04-05 Univ Leland Stanford Junior Metodos para mejorar terapia con anticuerpos antitumor.
SI2614082T1 (sl) 2010-09-09 2018-12-31 Pfizer Inc. Molekule, ki vežejo 4-1BB
DK2699598T3 (en) * 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER

Also Published As

Publication number Publication date
AR082916A1 (es) 2013-01-16
AU2014227437B2 (en) 2016-07-28
RU2710717C2 (ru) 2020-01-10
AU2014227437A1 (en) 2014-10-02
EP2614082B1 (en) 2018-10-03
TWI641621B (zh) 2018-11-21
CO6690759A2 (es) 2013-06-17
RU2013110576A (ru) 2014-10-20
JP6105470B2 (ja) 2017-03-29
RU2015110632A (ru) 2015-08-10
US8337850B2 (en) 2012-12-25
NZ700891A (en) 2017-05-26
AU2016204960A1 (en) 2016-08-04
MX2013002709A (es) 2013-05-22
US9468678B2 (en) 2016-10-18
JP2022046651A (ja) 2022-03-23
ES2699648T3 (es) 2019-02-12
US20180194851A1 (en) 2018-07-12
JP2017075164A (ja) 2017-04-20
BR112013005699B1 (pt) 2021-08-17
CN103221428B (zh) 2016-02-10
US20140377255A1 (en) 2014-12-25
KR20130080866A (ko) 2013-07-15
US10640568B2 (en) 2020-05-05
AU2011300445B2 (en) 2014-10-09
US8821867B2 (en) 2014-09-02
CA2810359A1 (en) 2012-03-15
SG188313A1 (en) 2013-04-30
WO2012032433A1 (en) 2012-03-15
RU2015110632A3 (enExample) 2018-11-30
PL2614082T3 (pl) 2019-02-28
JP2013544756A (ja) 2013-12-19
IL247054A0 (en) 2016-09-29
MY177065A (en) 2020-09-03
CA2810359C (en) 2021-06-22
IL225001A (en) 2016-08-31
TW201812011A (zh) 2018-04-01
MX337040B (es) 2016-02-09
PH12013500395A1 (en) 2013-04-22
PT2614082T (pt) 2018-12-03
JP2019065038A (ja) 2019-04-25
AU2011300445A1 (en) 2013-03-14
EP2614082A1 (en) 2013-07-17
SI2614082T1 (sl) 2018-12-31
TW201414748A (zh) 2014-04-16
HUE041958T2 (hu) 2019-06-28
SG10201506906VA (en) 2015-10-29
MX374682B (es) 2025-03-06
EP3441404A1 (en) 2019-02-13
IL250386A0 (en) 2017-03-30
TWI652345B (zh) 2019-03-01
BR112013005699A2 (pt) 2017-11-21
KR20130079533A (ko) 2013-07-10
TW201625694A (zh) 2016-07-16
US20120237498A1 (en) 2012-09-20
TWI425005B (zh) 2014-02-01
AU2018201703A1 (en) 2018-04-05
NZ729044A (en) 2020-07-31
PH12020550156A1 (en) 2024-01-15
US20160369000A1 (en) 2016-12-22
KR101527300B1 (ko) 2015-06-09
PE20131465A1 (es) 2014-01-04
RU2551963C2 (ru) 2015-06-10
PH12013500395B1 (en) 2020-10-16
NZ607710A (en) 2014-11-28
ZA201502914B (en) 2017-08-30
IL247054B (en) 2020-06-30
HK1187627A1 (zh) 2014-04-11
SG10201912092VA (en) 2020-02-27
TW201300413A (zh) 2013-01-01
CN105481983A (zh) 2016-04-13
MY162737A (en) 2017-07-14
HK1222872A1 (zh) 2017-07-14
DK2614082T3 (en) 2018-11-26
CN103221428A (zh) 2013-07-24
US20130078240A1 (en) 2013-03-28
JP6557648B2 (ja) 2019-08-07
AR114031A2 (es) 2020-07-15
KR101527297B1 (ko) 2015-06-26
TWI520969B (zh) 2016-02-11
CN105481983B (zh) 2021-09-03

Similar Documents

Publication Publication Date Title
NZ714128A (en) 4-1bb binding molecules
SG184310A1 (en) Antibodies that bind human cd27 and uses thereof
MX347164B (es) Anticuerpos anti-il-36r.
PH12013500810B1 (en) Anti-il-23 antibodies
MX2012006553A (es) Anticuerpos contra csf-1r humano y usos de los mismos.
PH12014502406A1 (en) Anti-il-23p19 antibodies
PH12014502826A1 (en) Immunoconjugates comprising anti-cd79b antibodies
TN2012000462A1 (en) Anti-cd40 antibodies
EP2729496B8 (en) Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains
PH12012501793B1 (en) Monoclonal antibodies against c-met
NZ626610A (en) Antibodies that bind csf1r
MX336001B (es) Anticuerpos anti-axl y metodos de uso.
MX2015000315A (es) Anticuerpos anti-cd22 e inmunoconjugados.
MX340555B (es) Anticuerpos contra il-18r1 y usos de los mismos.
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
NZ611785A (en) Anti-notch1 antibodies
MX336323B (es) Anticuerpos de anti-poliubiquitina y metodos de uso.
EP3019532A4 (en) CERTAIN IMPROVED HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
NZ724395A (en) Anti-pdgf-c antibodies
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
NZ757754A (en) Antibodies that bind csf1r
AU2008904175A0 (en) Improved domain antibodies
HK1197917A (en) Modulation of complement-dependent cytotoxicity through modifications of the c-terminus of antibody heavy chains

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 26 AUG 2018 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20180412

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2019 BY THOMSON REUTERS

Effective date: 20180721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2020 BY THOMSON REUTERS

Effective date: 20190725

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2021 BY THOMSON REUTERS

Effective date: 20200721

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2022 BY THOMSON REUTERS

Effective date: 20210701

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2023 BY THOMSON REUTERS

Effective date: 20220704

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 26 AUG 2024 BY THOMSON REUTERS

Effective date: 20230703

LAPS Patent lapsed